Phaseline

Targets › PTGES

PTGES (Prostaglandin E synthase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Jun 2027.

Terminal enzyme of the cyclooxygenase (COX)-2-mediated prostaglandin E2 (PGE2) biosynthetic pathway. Catalyzes the glutathione-dependent oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2) in response to inflammatory stimuli. (UniProt, O14684)

Open in Phaseline: the race on PTGES, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gesynta PharmaVipoglanstat
mPGES-1 (microsomal prostaglandin E synthase-1) inhibitor
PTGESPhase 2EndometriosisJun 2027

Conditions

Endometriosis (1)

Modalities

small molecule (1)

Companies

Gesynta Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.